Vaxart Reports Strong 2025 Financials, Awaits Key COVID-19 Trial Data
Event summary
- Vaxart reported $237.3M in revenue for 2025, up from $28.7M in 2024, driven by government contracts and the Dynavax collaboration.
- Phase 2b COVID-19 trial topline data from the 400-person sentinel cohort expected in early Q2 2026.
- Norovirus vaccine candidate demonstrated passive antibody transfer to infants via breast milk in Phase 1 results.
- Cash position of $63.8M as of December 31, 2025, with runway into Q2 2027.
The big picture
Vaxart's strong financial performance in 2025, driven by government contracts and strategic collaborations, positions it to capitalize on the growing demand for innovative oral vaccines. The upcoming Phase 2b trial data for its COVID-19 vaccine and the promising results from its norovirus vaccine candidate highlight the company's potential to address significant unmet medical needs. The biotech sector's focus on mucosal immunity and the shift towards pill-based vaccines underscore Vaxart's strategic relevance in the evolving vaccine landscape.
What we're watching
- Clinical Trial Outcomes
- The pace at which Vaxart's COVID-19 Phase 2b trial data will influence its strategic partnerships and funding prospects.
- Partnership Dynamics
- Whether the Dynavax collaboration will accelerate Vaxart's COVID-19 vaccine development and commercialization.
- Financial Sustainability
- How Vaxart will extend its cash runway beyond Q2 2027 through potential partnerships or non-dilutive funding.
Related topics